Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab deruxtecan study in metastatic castration-resistant prostate cancer
NL-OMON61101Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ifinatamab deruxtecan, abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started Aug 2025; status: active, not recruiting.
02
Drugs
ifinatamab deruxtecanabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON61101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61101.